Episodios

  • Episode 2 - "One in a Million"
    Jan 15 2024

    Did you know that there are over 400 different neurological conditions? The vast majority of these conditions are extremely rare, making them difficult to diagnose and treat. From a lack of available specialists, to fragmented care pathways, there are too many gaps in healthcare systems for people living with a rare neurological disease to fall through.

    In this episode of Brain Health Matters, we’ll hear from three people across Europe living with different rare neurological conditions. We’ll also hear from Astri Arnesen, President here at the European Federation of Neurological Associations (EFNA), who will tell us what organisations like EFNA, along with policy-makers, are doing to counter the challenges faced by the rare disease community.

    The Brain Health Matters podcast is written and produced by Elizabeth Cunningham, on behalf of the European Federation of Neurological Associations, with support from Roche, Novartis, Merck, Alexion and Horizon Therapeutics.

    Más Menos
    31 m
  • Episode 1 – “1 in 3”
    Dec 15 2023

    Neurological conditions are extremely common, with at least 1 in 3 of us affected in our lifetime. In this episode we’ll hear from people whose lives were turned upside down by the onset of symptoms and hear how they have coped since their diagnosis. 

    This episode features Gary Boyle, who lives with Young Onset Parkinson's Disease, Nadia Malliou, who lives with chronic pain and absence seizures, and Joke Jaarsma, who is affected by Restless Legs Sydrome. We'll also hear from Dr Orla Galvin, Executive Director at the European Federation of Neurological Associations (EFNA) and from two of our sponsors- Dimitrios Georgiopoulos, Head of Neurology & Immunology at Merck and Stephanie Ludwig, Global Patient Partnership Leader- Neuroscience at Roche.

    The Brain Health Matters podcast is written and produced by Elizabeth Cunningham, on behalf of the European Federation of Neurological Associations, with support from Roche, Novartis, Merck, Alexion and Horizon Therapeutics.

    Más Menos
    34 m